A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation.
Phase I clinical trial
breast cancer
carbon ion radiotherapy
hypofractionated radiotherapy
pathological evaluation
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
received:
16
08
2018
revised:
21
12
2018
pubmed:
26
2
2019
medline:
23
11
2019
entrez:
27
2
2019
Statut:
ppublish
Résumé
Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patients with low-risk Stage I breast cancer were eligible. A dose escalation study was designed, with dose levels of 48.0, 52.8 or 60.0 Gy relative biological effectiveness (RBE) administered in four fractions within 1 week. Three months after radiotherapy, the patients underwent tumor excision for pathological evaluation. Between April 2013 and December 2014, three cases receiving 48 Gy (RBE), three cases receiving 52.8 Gy (RBE) and one case receiving 60 Gy (RBE) underwent this protocol. No adverse effects were observed except for Grade 1 acute skin reaction in four cases. Pathological evaluation revealed that all four cases with doses of 52.8 Gy (RBE) and 60.0 Gy (RBE) achieved Grade 2b or more, but only two cases reached Grade 3. At the end of 2017, all cases were alive without recurrence or late had not caused any late adverse reaction. Carbon ion radiotherapy for Stage I breast cancer seems to be safe, and we found that it did not reach enough treatment effect 3 months after the treatment.
Identifiants
pubmed: 30805611
pii: 5364867
doi: 10.1093/jrr/rry113
pmc: PMC6530622
doi:
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-347Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
Références
J Thorac Oncol. 2007 Oct;2(10):916-26
pubmed: 17909354
Lung Cancer. 2009 Apr;64(1):45-50
pubmed: 18762351
Breast Cancer. 2011 Jan;18(1):10-7
pubmed: 20072824
Breast Cancer. 2011 Jan;18(1):3-9
pubmed: 20204556
Magn Reson Med Sci. 2010;9(1):31-6
pubmed: 20339264
Eur J Surg Oncol. 2012 Nov;38(11):1036-42
pubmed: 22947631
Chin J Cancer. 2013 Aug;32(8):441-52
pubmed: 23237221
Cancers (Basel). 2011 Oct 26;3(4):4046-60
pubmed: 24213124
Jpn J Radiol. 2014 May;32(5):288-95
pubmed: 24615166
Lancet Oncol. 2015 Feb;16(2):e93-e100
pubmed: 25638685
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):284-91
pubmed: 25754632
Phys Med Biol. 2015 Jul 21;60(14):5527-42
pubmed: 26133986
Jpn J Radiol. 2015 Sep;33(9):598-602
pubmed: 26219902
Med Phys. 2015 Aug;42(8):4419-22
pubmed: 26233171
J Vasc Interv Radiol. 2015 Nov;26(11):1652-7.e1
pubmed: 26342882
Eur Radiol. 2016 Nov;26(11):4037-4046
pubmed: 26852219
Clin Breast Cancer. 2016 Jun;16(3):145-54
pubmed: 26995159
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):11-8
pubmed: 27084617
Ann Surg Oncol. 2016 Aug;23(8):2438-45
pubmed: 27221361
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792